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INTRODUCTION
A recent study published in the Annals of Internal Medicine
revealed that nearly 10.8 million Americans are currently using e-
cigarettes.' Their popularity has increased drastically since they
came on the market in the mid-2000s.2 While the Food and Drug
Administration ("FDA") has acknowledged that, in general, they
* J.D. Candidate, Loyola University Chicago School of Law, 2020.
1 Mohammadhassan Mirbolouk et al., Prevalence and Distribution of E-
Cigarette Use Among US Adults: Behavioral Risk Factor Surveillance System,
2016, ANNALS OF INTERNAL MEDICINE (Aug. 2018).
2 See Jordan Paradise, No Sisyphean Task: How the FDA Can Regulatre
Electronic Cigarettes, 13 YALE JOURNAL OF HEALTH, POLICY, LAW, AND
ETHICS 1, 17 (2013).
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contain far fewer toxic chemicals and cancer causing agents than
traditional combustible tobacco products, it has been critical of
the perception that they are 'safer' because there is little
information on their long-term health risks. In order to address
this misconception, the FDA initially attempted to regulate
electronic nicotine delivery system ("ENDS") products as medical
devices under the Food, Drug, and Cosmetic Act, which has strict
requirements for premarket approval for safety and effectiveness.'
However, the D.C. Circuit ruled that absent overt therapeutic or
drug-like claims, ENDS products were considered "tobacco
products" to be regulated under the Family Prevention and
Tobacco Control Act ("TCA") of 2009.6
Thus, in regulating ENDS as tobacco products under the
TCA, the FDA has attempted to strike a balance between ensuring
that adults have access to ENDS as a viable alternative to
traditional combustible tobacco and sowing caution about their
unknown long-term effects. Complicating this delicate balance is
the recent surge in underage use of ENDS products.' In an effort
to address youth use of ENDS products, the FDA has engaged in
an "enforcement blitz," cracking down on ENDS manufacturers
and retailers.' However, the FDA's current enforcement policy
could result in ENDS products being regulated out of the market,'
thus leaving adults with no options for an alternative to traditional
combustible tobacco. The availability of ENDS products is of the
utmost importance to the 10.8 million consumers who use them,
due mostly in part to their smoking cessation abilities. Being able
to strike a balance between curbing youth use and ensuring these
products are available to consumers who need them is paramount.
That is why the FDA should take a backseat to state and local
3 See CENTER FOR DISEASE CONTROL, ELECTRONIC CIGARETTES
INFOGRAPHIC [hereinafter E-CIGARETTES INFOGRAPHIC],
https://www.cdc.gov/tobacco/basic-information/e-cigarettes/pdfs/Electronic-
Cigarettes-Infographic-p.pdf.
4 See id.
See Sottera, Inc. v. FDA 627 F.3d 891, 865 (D.C. 2010).
6 See id.
See Stacey Simon, FDA Proposes Regulations as Teen E-Cigarette Use
Skyrockets 78% in 1 Year, Am. CANCER SOCIETY (Nov. 21, 2018),
https://www.cancer.org/latest-news/fda-proposes-regulations-as-teen-e-
cigarette-use-skyrockets-7 8-percent-in- 1-year.html.
8 See Warning Letter from U.S. Food and Drug Admin., 2 (Sept. 12, 2018)
[hereinafter Warning Letter], https://www.fda.gov/mediall 19669/download.
Id. (FDA requiring Juul to remove flavored products from the market as
part of the crackdown).
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regulation, which is better equipped to achieve that balance.
Part I of this Article will briefly discuss the history the
FDA's attempts to regulate tobacco products. Part II will discuss
the rise of ENDS products in the U.S. and the FDA's response to
their popularity as a "healthier alternative" to traditional
combustible tobacco products. Part III will analyze what powers
the TCA grants to state and local governments and examine how
state and local governments have exercised their powers under the
TCA, demonstrating that they are in a better position to achieve
the FDA's goal of ensuring that ENDS products are not used by
underage consumers but also available to adults as a viable
alternative to traditional combustible tobacco products.
I. HISTORY OF FDA AND TOBACCO REGULATION
The Food and Drug Administration ("FDA") has long
struggled in its efforts to assert regulatory authority over tobacco
products. Congress passed The Food, Drug, and Cosmetic Act
("FDCA"), the enabling statute that grants the FDA power to
regulate food, drugs, and cosmetic products, in its original form in
1938.10 In addition to giving the FDA the authority to regulate
these areas, the FDA has general discretionary power to determine
whether a product is a food, drug, or cosmetic based on the
statutory language." The FDA has not, however, enjoyed the same
type of deference in its attempts to assert regulatory authority over
tobacco products under the FDCA.
In 1996, then FDA Commissioner David Kessler
announced that the FDA had determined that nicotine was a drug
and therefore fell under the jurisdictional authority of the FDA.1 2
The FDCA has a three-pronged definition for what constitutes a
"drug": A) articles recognized in the United States Pharmacopoeia;
B) articles intended for use in the diagnosis, cure, mitigation,
treatment, or prevention of disease; and C) articles (other than
food) intended to affect the structure or function of the body.' 3 The
FDA reasoned that since nicotine was an addictive substance
21 U.S.C. § 301 (1938).
1' See U.S. v. Bacto-Unidisk, 394 U.S. 784 (1969); National Nutritional
Food Ass'n. v. Mathews, 423 U.S. 827 (1975) (illustrating the Court's deference
to the FDA in determining what constitutes a food, drug, or cosmetic under the
FDCA).
12 See Regulations Restricting the Sale and Distribution of Cigarettes and
Smokeless Tobacco to Protect Children and Adolescents, 61 Fed. Reg. 44,397
(Aug. 28, 1996) (codified at 21 C.F.R. part. 801 et seq.).
13 21 U.S.C. 321(g)(1) (2006).
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affecting the "structure or function of the body" and had significant
pharmacological effects, it could be regulated as a drug under the
statute.14 Similarly, the FDA determined that cigarettes and
smokeless tobacco were drug delivery devices" because they
constituted "an instrument, apparatus, implement, machine,
contrivance, implant, in vitro reagent, or other similar or related
article, which. . .was intended to affect the structure or any
function of the body" 6 by delivering nicotine to the body. The
FDA promulgated a slew of regulations that attempted to address
the known health risks of tobacco products and limit youth
access." These regulations were met with harsh criticism by the
tobacco industry and prompted a challenge of the FDA's authority
to regulate nicotine as a drug, and therefore, cigarettes and
smokeless tobacco as drug delivery devices.
In FDA v. Brown- Williamson, the Supreme Court
addressed the issue of whether or not the FDA had statutory
authority to regulate tobacco products under the FDCA.'` The
Court found that the FDA lacked regulatory authority over
tobacco products because "Congress specifically intended to
exempt tobacco from the FDA's regulatory purview."" It
determined that nothing in the FDCA specifically addressed
tobacco products, and given subsequent tobacco-specific
legislation, "it was plain that Congress never intended the FDA to
regulate tobacco under the FDCA."2 0 Most importantly, however,
the Court found that the motivating factor for the drug provisions
of the FDCA was to ensure safety and efficacy of drugs prior to
market and considering the known health risks of tobacco
products, their inherent danger would require the FDA to remove
them from the market entirely, "something that Congress surely
did not intend."2 ' After the Brown- Williamson decision, the FDA
withdrew its regulations, leaving the tobacco industry untouched
by FDA regulatory authority until Congress acted nine years later
" See Regulations Restricting the Sale and Distribution of Cigarettes and
Smokeless Tobacco to Protect Children and Adolescents, 61 Fed. Reg. 44,397
(Aug. 28, 1996).
1 See id. at 44,402.
16 21 USC § 321(h).
17 See Regulations Restricting the Sale and Distribution of Cigarettes and
Smokeless Tobacco to Protect Children and Adolescents, 61 Fed. Reg. at 44,687
(Aug. 28, 1996).
18 529 U.S. 120 (2000).
1 Id. at 12 1.
20 Id. at 161.
21 Id. at 121-22.
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by passing The Family Smoking Prevention and Tobacco Control
Act of 2009 ("TCA").22
The TCA was Congress's response to the Brown-
Williamson decision. It amended the FDCA to give the FDA
regulatory authority over tobacco products, including cigarettes
and smokeless tobacco and their manufacturers.23 Specifically, the
TCA created the Center for Tobacco Products within the FDA, 24
and defined a tobacco product as "any product made or derived
from tobacco that is intended for human consumption, including
any component, part, accessory of a tobacco product (except for
raw materials other than tobacco used in manufacturing
component, part, or accessory of a tobacco product)."" Under the
TCA, manufacturers of tobacco products are subject to
manufacturing guidelines laid out by the FDA, disclosure of
ingredients, health and safety information reporting, and
advertising and packaging requirements. 26 These regulations were
crucial to the TCA's mission of raising awareness of the adverse
health effects of tobacco products, reducing the number of
Americans who use tobacco products, and ensuring that underage
consumers could not get their hands on them.2 7 While the TCA has
no doubt contributed to the decline in the number of youth and
adults who use traditional tobacco products,2 8 the relatively recent
advent and increased use of electronic cigarettes has produced a
completely new set of regulatory challenges for the FDA.
II. RISE OF ELECTRONIC CIGARETTES IN THE U.S. AND
FDA's REGULATORY AUTHORITY
The development of e-cigarettes can be traced to Hon Lik,
a Chinese pharmacist and inventor who, in 2003, developed the
product as an attempt to create safer alternative to traditional
cigarettes. 29 Lik's company, Ruyan, is responsible for bringing the
22 21 U.S.C. § 387.
23 See21 U.S.C. § 387(a).
24 See 21 U.S.C. § 387a(e) (2006).
25 21 U.S.C. § 201(rr)(1) (2006).
26 See 21 U.S.C. § 387d-g (2006).
27 See Family Smoking Prevention and Tobacco Control Act, Pub. L. No.
111-31, § 2, 123 Stat. 1776 (2009) (codified as amended in scattered sections of 5
U.S.C., 15 U.S.C., and 21 U.S.C. (2006)).
28 See CDC MORBIDITY AND MORTALITY WKLY. REP. 44 (2015),
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6444a2.htm?scid=mm64
44a2_w.
" See Jonathan Foulds et al., Electronic Cigarettes (E-Cigs): Views of
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first e-cigarette to market in the U.S. in the mid-2000s.3 0 The
modern e-cigarettes are smokeless, battery-operated devices that
people use to inhale an aerosol, typically containing nicotine,
flavoring, and other chemicals." Most ENDS consist of three
parts: the nicotine cartridge, an atomizer which vaporizes the
nicotine, and a rechargeable battery.3 2 The main appeal of ENDS
products is that they do not contain tobacco and lack many of the
additives found in traditional cigarettes, leading manufacturers to
claim that ENDS are a healthier alternative to traditional
cigarettes."
The health related and smoking cessation claims related to
ENDS has put the FDA in a difficult position. Since ENDS are a
relatively new phenomena, there are no studies showing their long-
term health risks. However, the FDA has generally embraced them
as a safer alternative to traditional combustible tobacco products
because they contain far fewer toxic chemicals and cancer causing
agents.3 4 Being safer than traditional combustible tobacco
products, however, doesn't necessarily render them "safe," as
many ENDS still contain potentially harmful substances like
heavy metals, volatile organic compounds, and cancer-causing
agents." Therefore, the FDA was put in the precarious position of
trying to ensure that adult smokers have access to a safer
alternative to traditional combustible tobacco products and
navigating the treacherous regulatory waters associated with an
innovative product for which there is little long-term health risk
information. The problems stemming from this dichotomy came to
a head in Sottera Inc. v. FDA 6 in 2010.
Due to the drastic increase in Americans using ENDS in the
late 2000s, 37 the FDA sought to assert regulatory authority over
Aficionados and Clinical/Public Health Perspectives, 65 INT'L J. CLINICAL
PRAC. 1037, 1037 (2011).
o See U.S. Patent No. 7,832,410 (filed Mar. 18, 2005).
31 See NATIONAL INSTITUTE ON DRUG ABUSE, DRUGFACTS -
ELECTRONIC CIGARETTES (2018),
https://www.drugabuse.gov/publications/drugfacts/electronic-cigarettes-e-
cigarettes.
32 See id.
31 See UMDNJ, Trinkets and Trash: Artifacts of the Tobacco Epidemic
(searching for e-cigarette manufacturers marketing claims).
34 See E-CIGARETTES INFOGRAPHIC, supra note 3.
3s See id.
36 627 F.3d 891(D.C. Cir. 2010)
3 See John Tierney, A Tool to Quit Smoking Has Some Unlikely Critics,
N.Y. TIMES
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ENDS as medical devices under the FDCA. 8 As stated above, the
FDCA permits the FDA to regulate medical devices under a strict
statutory framework that requires rigorous pre-market testing for
safety and effectiveness prior to approval.3 9 The FDA's main
argument was that ENDS were medical devices because they were
marketed as smoking cessation products and thus "intended to
affect the structure or function of the body, and to prevent,
mitigate, or treat the withdrawal symptoms of nicotine
addiction." 4 0 However, the D.C. Circuit held that there was
insufficient evidence that Sottera was making therapeutic claims
about its ENDS and, therefore, its products were considered
tobacco products and not medical devices. 41 The court reasoned
that Sottera was marketing their products for smoking pleasure
rather than a therapeutic reason or for smoking cessation.4 2
Further, the court relied heavily on the Brown- Williamson
decision, emphasizing that unless the manufacturer is making
drug-like claims, tobacco products are exempt from the FDCA's
drug/medical device regulatory framework.4 3 Significantly, for the
first time, this created a presumption that ENDS are tobacco
products to be regulated under the TCA. In response to the ruling,
the FDA chose not to appeal the decision to the Supreme Court
and, instead choosing to officially assert its regulatory authority
over ENDS as tobacco products under the TCA.44
A. FDA Deems ENDS as Tobacco Products
Pursuant to the Sottera decision, the FDA promulgated
regulations deeming ENDS as tobacco products and subject to
regulation under the TCA.4 5 Significantly, ENDS. products are
now subject to the same regulatory requirements as traditional
tobacco products under TCA § 387.46 ENDS manufacturers now
must comply with industry manufacturing practices and
(Nov. 8, 2011), http://www.nytimes.com/2011/11/08/sciencele-cigarettes-help-
smokersquit-but-they-have-some-unlikely-critics.html.
3 See Sottera, Inc. v. FDA, 627 F.3d 891 (D.C. Cir. 2010).
3 See 21 U.S.C. 201(h).
40 Sottera, 627 F.3d at 65.
41 1dat 898.
42 Id. at 893.
43 See id.
14 See 81 Fed. Reg. 28,974 (May 10, 2016) (codified as 21 C.F.R._part. 1100
et seq.).
45 See id.
46 See21 U.S.C. § 387.
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advertising and retail requirements, as well as provide a list of
ingredients and health/safety information to the FDA and the
public.4 7 Additionally, ENDS products are subject to the same
adulteration and misbranding provisions that allow the FDA to
commence enforcement actions such as seizures and injunctions.4 8
Most notable for this discussion, however, is ENDS
applicability as "new tobacco products" under the TCA. A "new
tobacco product" is "any tobacco product that was not on the
market in the U.S. as of 2007" or "was modified since 20o7."49
Considering almost all ENDS products currently on the market
came after 2006, ENDS qualify as "new tobacco products" under
the statute. Significantly, "new tobacco products" are subject to
pre-market review for safety.so Pre-market review requires "new
tobacco products" to submit any health and safety information
related to the product, ingredients, methods for use, and clinical
data if available." The application would then have to be
approved by the FDA prior to the ENDS manufacturer bringing
the product market.5 2 Requiring ENDS to submit to pre-market
approval would significantly hamper their ability to get to market
and therefore limit the options for adults looking to switch from
traditional combustible tobacco to ENDS." The FDA is again put
in the difficult position of ensuring that ENDS products are safe
for use but also available to adults as an alternative to traditional
combustible tobacco.
B. FDA Exercises Enforcement Discretion
In May 2017, the FDA issued a guidance in which it stated
that it was exercising its enforcement discretion by waiving the
pre-market approval requirement for ENDS as "new tobacco
products."" Essentially, ENDS manufacturers were free to bring
their products to market without going through the rigorous pre-
47 See 21 U.S.C. § 387d-e.
48 See21 U.S.C. § 387b-c.
49 21 U.S.C. § 387j(a)(1).
s0 21 U.S.C. § 387j(a)(2).
s" See 21 U.S.C. § 387j(b)(1).
52 21 U.S.C. § 387(c).
" See Warning Letter, supra note 8 at 1 (threatening to require Juul to
submit to -pre-market approval and take its products off the market until
approved).
14 See U.S. FOOD & DRUG Ass'N, EXTENSION OF CERTAIN TOBACCO
PRODUCT COMPLIANCE DEADLINES RELATED TO THE FINAL DEEMING RULE:
GUIDANCE FOR INDUSTRY (2018).
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market review process typically required." In March 2019, then
Commissioner Scott Gottlieb released a statement confirming that
the exercise in enforcement discretion was intended to "encourage
the development of products that can deliver nicotine to currently
addicted adult smokers without all of the harmful effects of
combustion." 6 In that same statement, however, Gottlieb
acknowledged that more than 3.6 million middle school and high
school students were current ENDS users - up 1.5 million from
2016-2017.s' In response to this troubling statistic, Gottlieb
announced the FDA was reconsidering its enforcement discretion
policy and focusing on protecting youth from becoming addicted
to nicotine.5 The FDA's attempt to address the youth use statistics
began with a ramped up enforcement effort aimed at retailers
selling ENDS to minors.
C. FDA's Cracks Down on ENDS
In response to the rising number of underage ENDS users,
the FDA engaged in an "enforcement blitz" of ENDS retailers,
issuing 1,100 warning letters and 130 monetary penalties for
retailers selling ENDS to minors. Most notably, the FDA sent a
warning letter to Juul Labs, Inc. 6 0 ("Juul"), which, as of September
2018, has the largest market share of the ENDS market at 72%.61
The warning letter detailed the FDA's enforcement actions to
address youth use of ENDS and threatened to end its enforcement
discretion, and subject Juul products to pre-market review, if it did
not comply with FDA recommendations.6 2 In effect, this would
require Juul to pull their products from the market as they would
5 See id. at 3.
56 See Press Release, Scott Gottlieb, Commissioner, U.S. Food and Drug
Admin. Commissioner Statement on Advancing New Policies Aimed at
Preventing Youth Access to, and Appeal of, Flavored Tobacco Products,
Including E-Cigarettes and Cigars (March 13, 2019),
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm 63 3 29
Lhtml.
5 See id.
58 See id
59 See Warning Letter, supra note 8.
60 See id.
61 See Richard Carver, Julu Expands E-Cig Market Share Gap with
Reynolds Vuse, WINSTON-SALEM JOURNAL (Aug. 25, 2018),
https://www.journalnow.com/business/juul-expands-e-cig-market-share-gap-
with-reynoldsvuse/article_0bb4d442-fc0f-5cOO-8b05-29bbf95dc985.html.
62 See Warning Letter, supra note 8.
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be considered adulterated under the statute. In order to address
the youth use of its products, the FDA requested that Juul
discontinue sales to retail establishments that have been subject to
an FDA civil monetary penalty-for sale of tobacco products to
minors within the prior twelve months, develop or strengthen any
internal program to check on retailers, eliminate online sales or
prove that their online sales are not ending up in youth hands, and
revise current marketing practices to ensure youth are not being
targeted.64
Juul's CEO Kevin Burns released an "action plan" to
address youth use of its products. 6 s Juul agreed to stop selling
flavored nicotine pods to all 90,000 of its retail stores, restricted
flavors to adults 21+ on their website, strengthened retail
compliance, overhauled its social media and advertising practices,
and developed new technology to restrict youth access.66
Considering Juul's substantial market share, it has the ability to
work with the FDA while also ensuring that some of its products
stay on the market and continue to generate revenue. Similar
actions would likely spell disaster for a smaller, independent
ENDS manufacturer who could not afford to remove products and
flavors in an effort to comply with FDA mandates. This begs the
question of whether the FDA's heavy handed, top-down approach
is the best way to regulate the ENDS market.
III. STATE AND LOCAL GOVERNMENT POWERS UNDER
THE TCA
While the TCA affords most of its regulatory authority to
the FDA, it preserves some important aspects for state and local
governments, giving these local governments the tools to better
address youth use of ENDS than the FDA. Specifically, the TCA
preempts state and local governments from establishing any
requirement which is different from, or in addition to, the FDA
requirements for tobacco product standards, premarket review,
adulteration, misbranding, labeling, registration, good
manufacturing standards, or modified risk tobacco products.67 The
6 See 21 U.S.C. § 387b-c.
64 See Warning Letter, supra note 8 at 3.
6s See Press Release, Kevin Burns, CEO, Juul Labs, Inc. Action Plan to
Address Teen Use (Nov. 13, 2018), https://newsroom.juul.com/2018/11/13/juul-
labs-action-plan/.
66 I[d.
67 See 21 U.S.C. § 387p(a)(2)(A).
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regulatory authority afforded to the FDA focuses on
manufacturing rather than retail, with most enforcement actions
limited to seizures and injunctions against manufacturers for
adulteration and misbranding violations. 8 While effective in
scaring companies like Juul into compliance,' this heavy-handed
enforcement approach limits consumer choice in ENDS products
and stifles innovation by forcing companies to pull products from
the market or be regulated out of existence. The powers left to state
and local governments allow for a more retail-focused enforcement
approach, which is nimbler and more responsive to consumers.
The TCA grants state and local governments regulatory
authority of ENDS in several key areas which can be utilized to
address youth use of ENDS. The TCA preserves the right for state
and local governments to enact and enforce laws in addition to, or
more stringent than, what is required by the FDA relating to the
sale, distribution, possession, or access to, and advertising and
promotion of ENDS products. 0 Additionally, state and local
governments are free to tax ENDS products as they see fit.71 In
effect, the law gives state and local government autonomy over
five distinct areas of ENDS regulation: taxation, licensing, age
requirements, advertising/promotion, and information reporting.7 2
Therefore, state and local' governments have the power to address
youth use at the access point, which is more effective than the
FDA's top-down approach at ensuring that adults still have access
to an alternative to traditional combustible tobacco.
A. Taxation
By enacting an excise tax on ENDS products, states can
limit youth access while ensuring that adults still have access to an
alternative to traditional combustible tobacco products. As of
January 2019, nine jurisdictions have enacted an excise tax on
ENDS products: Minnesota, Pennsylvania, North Carolina, West
Virginia, Kansas, Louisiana, Washington D.C., and California.
68 21 U.S.C. § 387(a)-(b).
6 See Supra FDA Cracks Down on ENDS.
7o See 21 U.S.C. 387p(a)(1).
71 See id.
72 See Michael Freiberg, Options for State and Local Governments to
Regulate Non-Cigarette Tobacco Products, ANNALS OF HEALTH LAW, Vol. 21:
Iss. 2 (2012).
1 TOBACCO CONTROL LEGAL CONSORTIUM, STATES WITH LAWS TAXING
E-CIGARETTES (2018), https://publichealthlawcenter.org/sites/default/files/E-
Cigarette-Legal-Landscape-50-State-Review-March-2019.pdf.
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Additionally, three states are home to local municipalities that
have enacted an excise tax on ENDS products sold in their
jurisdiction: Alaska, Illinois, and Maryland.14 States such as
Pennsylvania, Minnesota, and California, elect to place a tax on a
percentage of the wholesale price of the product as in," while
others like Kansas, Louisiana, North Carolina, and West Virginia
elect to place a tax per milliliter of nicotine liquid sold.7 6 The
wholesale taxes range from the highest at 95% of the product price
in Minnesota, to the lowest at 40% in Pennsylvania." The per
milliliter tax generally hovers around .05% per ml in most states
that choose that application. The differences in application and
amount illustrate the accountability and flexibility state and local
governments possess which the FDA lacks.
Most importantly, empirical research shows that states that
have implemented an excise tax on ENDS products have
successfully reduced the number of units sold. For example, a
recent study in Minnesota demonstrates that enacting excise taxes
on ENDS products can lead to a decline in use.79 In 2013,
Minnesota raised its taxes on ENDS products from 70% to 95% of
the wholesale price.o The study took data on the sales of ENDS
products in convivence stores in Minneapolis, Minnesota during
2012 and 2013 and compared it to data from sales of ENDS
products in convivence stores in St. Louis, Missouri during the
same time period."' Specifically, the study focused on the sales data
of two ENDS manufacturers, NJOY and Blu, as they were the two
highest selling brands in both cities at the time.8 2 In the months
prior to the tax increase, which took place on July 2013, both cities
had relatively the same number of ENDS units purchased." After
the tax increase, however, their research showed that sales of e-
cigarettes in Minneapolis "steadily declined, reaching a nadir of
74 See Scott Drenkard, Vapor Taxes by State-2018, TAX FOUNDATION,
(Mar. 28, 2018), https://taxfoundation.org/vapor-taxes-2018/.
" See id.
76 See id.
77 
_[d.
78 Ird
79 Michael S. Amato & Raymond G. Boyle, Evaluating an Excise Tax on
Electronic Cigarette Consumption: Early Result, TOBACCO REGULATORY
SCIENCE (2016).
so See id. at 124.
* Seeid. at 125 (mentioning that St. Louis didn't have an ENDS excise tax
in place during the same time period).
82 See ld.
83 See id at 130.
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40% below expected values approximately 4 months later." 8 4 Also
notable was that the researchers found evidence that the prices of
all ENDS products increased by more than the amount of the tax
increase, indicating that the common tobacco industry practice of
over-shifting prices to consumers after tax increases is also
prevalent in the ENDS industry."
The empirical study clearly demonstrates that increased
taxes on ENDS products can lead to a decline in number of units
sold in comparison to state lacking such a tax. While the study did
not differentiate between youth and adult use, it can be
extrapolated that a decline in overall use coincided with a decline
in youth use. Therefore, raising taxes on ENDS products is a viable
means of reducing youth use while also ensuring their availability
to adults who are willing to pay for them.
However, there is evidence that retailers that sell ENDS
products have been forced to close in states that have enacted
similar taxes, thus reducing options for adults looking to switch.8 6
This unfortunate consequence is a result of a state enacted policy
for which legislators are accountable and can be justified based on
the will of state's citizens. Additionally, states like Pennsylvania
have still been receiving millions in tax revenue even though many
ENDS retailers have closed." This proves that while some retailers
have closed, ENDS products are still available to adults who want
them. This would not be the case if the FDA forced manufacturers
to pull products from their shelves as they would not be available
anywhere and both retailers and consumers would be negatively
affected. Therefore, a state imposed excise tax is a better
alternative to curb youth use of ENDS products and ensure they
are still available to adults than unilateral action by the FDA
against a manufacturer.
84 Id. Notably, while the number of ENDS units sold in St. Louis also
showed a slight decline in the same time period, it was to a far lesser extent than
in Minneapolis.
85 See id.
86 See Michael Carroll, More Pennsylvania Vape Shops Expected to Close
Unless Tax is Repealed, PENN. WATCHDOG, (Oct. 4, 2017),
https://www.watchdog.org/pennsylvania/more-pennsylvania-vape-shops-
expected-to-close-unless-tax-is/article_3e42b7fc-a7df-11e7-a229-
7f3c9038a908.html.
87 See Justine McDaniel, Pennsylvania's Vape Tax Brings in Millions but
100-plus Businesses Close, PHILADELPHIA INQUIRER (Sept. 11, 2017),
https://www.wtae.com/article/pennsylvania-vape-tax-businesses-
close/12222304.
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B. Increased Age Requirements
Increasing age requirements is another tool that state and
local governments can employ to curb youth use of ENDS
products while ensuring that they are still available to adults. As
of January 2019, ten states have raised the minimum age for the
purchase tobacco products." Seven states have raised the
minimum age to twenty-one, as well as many localities including
Chicago, New York, and Washington D.C.8 9 Three other states
have raised the minimum age to 19."
Increased age requirements are supported by a 2015 study
by the National Institute of Medicine ("NIM") which suggests that
raising the minimum age for -tobacco purchases to twenty-one
would have a significant impact on youth access in the U.S.91 It
found that the most significant factor of youth use of tobacco was
easy access prior to eighteen.9 2 This is largely attributed to younger
teens having access to eighteen year old peers who can purchase
tobacco for them.93 If, however, the age were raised to twenty-one,
those who can legally obtain tobacco are less likely to be in the
same social networks as high schoolers, limiting teens' ability to
access tobacco. 94 The NIM's projection was substantiated in a
recent empirical study focusing on the impact of California's
decision to raise the minimum legal age for tobacco products to
twenty-one, including ENDS products.
In June 2016, California raised the minimum legal age for
the purchase of tobacco products to twenty-one.9 6 Seven months
after the law went into effect, researchers evaluated four statewide
tobacco purchase surveys and assessed retailer violation rates on
tobacco sales.97 The study found that retailer violations for selling
88 TOBACCO CONTROL LEGAL CONSORTIUM, STATES WITH LAWS
RESTRICTING YOUTH ACCESS TO TOBACCO (2018). All include ENDS in their
definition of "tobacco product."
89 I-d
90 Id
91 NATIONAL INSTITUTE OF MEDICINE, PUBLIC HEALTH IMPLICATIONS
OF RAISING THE MINIMUM AGE OF LEGAL ACCESS TO TOBACCO PRODUCTS
(2015) [hereinafter NIM].
92 Seeid at 2.
3 See id
94 See id
95 See Xueying Zhang, et. al., Evaluation of California's Tobacco 21 Law,
TOBACCO CONTROL, Vol. 27: Iss 6 (2018)
96 See id. at 656.
9 See id.
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tobacco and ENDS products to underage persons had decreased
significantly - from 10.3% to 5.7%. The study attributed the
decrease in violations partly due to increased vigilance on the part
of retailers, but more significantly, teens were less likely to even
attempt to purchase tobacco products due to the law."
This empirical evidence that regarding the law's deterrent
effect supports the conclusion that it is the access point that is most
crucial at stopping teen use. Additionally, as the NIM study
indicates, one of the main factors contributing to underage use of
tobacco products is youth access to peers who can purchase
products for them. 9 This can be extrapolated to include ENDS
products, as it's easy to assume eighteen year-olds are also buying
ENDS products for their underage peers. Therefore, by raising the
minimum age to twenty-one, states can undercut what research
suggests is one of the most significant factors leading to underage
use of ENDS products. Conversely, raising the minimum age has
no negative effect the availability of ENDS products to adults.
Where the FDA can only require manufacturers to comply with
stricter regulations or be forced to pull their products off shelves, a
state imposed age increase directly addresses the root of the
problem and has no effect on the availability of ENDS products
for adults.
C Licensing
State and local governments can impose stricter licensing
requirements on retail stores that sell ENDS products with hefty
fines associated with non-compliance or underage sales. As of
January 2019, twenty-one states have implemented licensing
requirements for retail sales of ENDS products.100 Licensing
enables the state or local government to maintain a comprehensive
list of businesses that sell ENDS products which can be used to
monitor the number, location, and density of retailers in the
locality.'0o Typical licensing requirements include being approved
as an ENDS retailer by the state, complying with local and state
ordinances regarding retail location and advertising, paying an
annual licensing fee (which often covers the costs of inspection and
enforcement), and agreeing to increased monitoring and
9 See id. at 660.
99 NIM, supra note 91.
100 TOBACCO CONTROL LEGAL CONSORTIUM, STATES WITH LAWS
REQUIRING LICENSES FOR RETAIL SALES OF E-CIGARETTES (2018).
101 See COUNTERTOBACCO.ORG,
https://countertobacco.org/policy/licensing-and-zoning/.
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information reporting.102 In addition to these requirements,
licensed retailers are often subject to stricter penalties for non-
compliance and underage sales than their non-licensed
counterparts. For example, in Washington state, operating a retail
store that sells ENDS products without a license is codified as a
class C felony.103 Additionally, if a licensed store is found selling to
minors, it is subject to increased fines and possible license
revocation.10 4 By requiring retailers to submit to increased
monitoring and subjecting them to increased penalties, states can
effectively limit youth access by discouraging bad behavior and
encouraging increased retailer vigilance.
In addition to encouraging compliance, licensing can be an
effective tool to effectively regulate the location, density, and
number of ENDS retailers. While licensing requirements for
ENDS retailers are too recent for reliable data illustrating their
effect on youth use, it can be assumed that a similar licensing
system employed by states to regulate traditional tobacco retailers
can be extrapolated to ENDS retailers. For example, a 2006 study
by the National Institute of Health found that a high density of
tobacco retailers in a community is often associated with high rates
of youth use.o10 There is no reason why this could not also hold true
for a high density of ENDS retailers, especially considering many
retailers sell both traditional and ENDS products. By limiting the
number of ENDS retailers in a given area, states and localities can
effectively curb youth use without completely eliminating options
for adults. For example, the San Francisco Tobacco-Free Project,
a subset of the San Francisco Department of Public Health, did a
case study of the tobacco retail density policy San Francisco
implemented in January 2015.106 The policy put a cap on the
number of new tobacco permits issued per district, prohibited a
new permit to be issued within 500 feet of a school or another
tobacco permit holder, and put an outright ban on permits for bars
and restaurants. 07 Just one year after the policy was implemented,
the number of tobacco retailer licenses across the city decreased by
102 See id.
103 WASH. REv. CODE § 70.345.040.
104 WASH. REV. CODE § 70.345.180.
15 See Scott P. Novak, et. al., Retail Tobacco Outlet Density and Youth
Cigarette Smoking: A Propensity-Modeling Approach, Am. J. PUB. HEALTH
(2006).
106 See BRIGHT RESEARCH GROUP FOR THE SAN FRANCISCO TOBACCO-
FREE PROJECT, REDUCING TOBACCO RETAIL DENSITY IN SAN FRANCISCO: A
CASE STUDY (2016).
107 .See id. at 10.
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8%.os Additionally, districts with the highest densities saw the
largest decreases. 09 While the data on the effect of this policy on
youth use is not available as of yet, it seems logical to assume that
less exposure and access would lead to less use. Therefore, it
follows that employing similar licensing density policies as applied
to ENDS retailers may result in decreased youth use without
significantly impeding adult access.
CONCLUSION
State and local governments, rather than the FDA, are in
the best position to regulate ENDS products to curb youth use. The
tools left to the states and localities under the TCA are better suited
for addressing the underlying issue of youth access at retail
locations without limiting options for adults who want an
alternative to traditional combustible tobacco products. As
indicated by the research used in support of the arguments for
increased taxes, increased age limits, and increased licensing
requirements, the main issue with youth use of ENDS is easy
access. While the FDA can monitor retail locations, issue fines, and
send warning letters, their main enforcement actions are mostly
remedial in nature and limited to drastic measures that force
manufacturers into compliance but limit access for adult
consumers. State and local governments, on the other hand, have
the ability to enact proactive legislation tailored to the needs of
their communities and have been empirically proven to limit youth
access while also having a minimal effect on adult access to an
alternative to traditional combustible tobacco. If the FDA is
serious about its promise to ensure that adults have access to
innovative products that are safer than traditional combustible
tobacco, it should let states and localities address youth use at the
retail level.
.o. See id. at 13.
109 See id.
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